Search Results
Your search for Ruben A. Mesa, MD matches 28 pages
Showing 1 - 28Syed Ali Abutalib, MD, Moves to Advocate Health to Lead Hematology, Transplant Programs
Syed Ali Abutalib, MD, is taking his talents to the recently affiliated Aurora Health Care, now part of Advocate Health, one of the largest integrated health systems in the United States. He accepted a new position at Aurora St. Luke’s Medical Center in Milwaukee, where he is now Director of the...
FDA Approves Momelotinib for Patients With Myelofibrosis and Anemia
On September 15, the U.S. Food and Drug Administration (FDA) approved momelotinib (Ojjaara) for the treatment of intermediate- or high-risk myelofibrosis, including primary myelofibrosis or secondary myelofibrosis (post–polycythemia vera and post–essential thrombocythemia), in adults with anemia....
ASCO Remembers Former Board of Directors Member and Radiation Oncologist A. William Blackstock, Jr, MD, FASCO
ASCO is deeply saddened by the death of A. William Blackstock, Jr, MD, FASCO, who served on the Society’s Board of Directors from 2018 to 2022. Dr. Blackstock passed away on June 18, 2023, from complications of prostate cancer. He was 60 years old. “We mourn the passing of a friend and colleague...
Traveling the World at an Early Age Gave Perspective and Balance to Future Oncology Leader Derek Raghavan, MD, PhD
In this installment of The ASCO Post’s Living a Full Life series, guest editor Jame Abraham, MD, FACP, spoke with Derek Raghavan, MD, PhD, FACP, FRACP, FASCO, Founding President of the Levine Cancer Institute. Established in 2011, the Levine Cancer Institute is part of Atrium Health (formerly the...
Atrium Health and Wake Forest University School of Medicine Cancer Program Appoint New Director
Atrium Health recently announced that Ruben A. Mesa, MD, FACP, has been named President and Executive Director of its cancer service line—which includes both Atrium Health Levine Cancer Institute and Atrium Health Wake Forest Baptist Comprehensive Cancer Center—and Vice Dean for Cancer Programs at...
Momelotinib for Symptomatic and Anemic Patients With Myelofibrosis
Once-daily treatment with the oral JAK1/2 and ACVR1/ALK2 inhibitor momelotinib significantly improved outcomes of patients treated for myelofibrosis. Ruben Mesa, MD, FACP, and colleagues presented results of the MOMENTUM phase III randomized study, which evaluated momelotinib vs danazol in...
Ruben A. Mesa, MD, on Myelofibrosis: Phase III Results on Momelotinib vs Danazol
Ruben A. Mesa, MD, of Mays Cancer Center at UT Health San Antonio MD Anderson Cancer Center, discusses new findings from the MOMENTUM study. This trial showed that in symptomatic and anemic patients with myelofibrosis, momelotinib was superior to danazol for symptom and spleen responses, as well as ...
AACI Members Choose Robert Winn, MD, as Vice President/President-Elect, and Other New Leaders
Robert Winn, MD, Director of Virginia Commonwealth University (VCU) Massey Cancer Center, has been elected by the members of the Association of American Cancer Institutes (AACI) to serve as Vice President/President-Elect of AACI’s Board of Directors. Dr. Winn’s new position is effective...
Majority of Patients With Cancer Achieve Immune Response After COVID-19 Vaccination
In a U.S. and Swiss study, nearly all patients with cancer developed an immune response to COVID-19 mRNA vaccines 3 to 4 weeks after receiving their second dose. However, a small group of the patients exhibited no response, raising questions about how their protection against the virus will be...
Novel Targeted Agents for the Treatment of Myelofibrosis
“Progress lies not in enhancing what is, but in advancing toward what will be.” –Kahlil Gibran To complement The ASCO Post’s continued comprehensive coverage of the 2020 American Society of Hematology (ASH) Annual Meeting &...
Ruben A. Mesa, MD, on Myelofibrosis, Transfusion Independence, and Momelotinib
Ruben A. Mesa, MD, of UT Health San Antonio Cancer Center, discusses new findings on momelotinib, a potent JAK1, JAK2, and ACVR1 inhibitor with clinical activity against hallmark features of myelofibrosis such as anemia and splenomegaly. Results showed that transfusion independence was associated...
Selected ASH Abstracts on Novel Treatments of Polycythemia Vera
To complement The ASCO Post’s continued comprehensive coverage of the 2020 American Society of Hematology (ASH) Annual Meeting & Exposition, here are three abstracts selected from the meeting proceedings focusing on novel therapies for polycythemia vera. For full details of these study...
Breast Cancer and Radiation Researcher David Gius, MD, PhD, Joins Mays Cancer Center
David Gius, MD, PhD, a breast cancer and radiation researcher, has joined the Mays Cancer Center, home to The University of Texas Health San Antonio MD Anderson. He was recruited to the Mays Cancer Center from the Robert H. Lurie Comprehensive Cancer Center at Northwestern University with a $6...
Fedratinib: Back From Development Limbo for the Treatment of Myeloproliferative Neoplasms
In September 2019, Dr. Claire Harrison and colleagues, myself among them, presented two new analyses regarding the use of the JAK2 and FLT3 inhibitor fedratinib in myelofibrosis at the Society of Hematologic Oncology (SOHO) Annual Meeting, with resulting publication in Clinical Lymphoma, Myeloma...
Study Findings on Myeloproliferative Neoplasms Including Systemic Mastocytosis
HERE IS AN UPDATE on six different studies featured at the 2018 American Society of Hematology (ASH) Annual Meeting & Exposition. Topics focused on novel treatments for myelofibrosis, polycythemia vera and essential thrombocythemia, as well as systemic mastocytosis. Myelofibrosis ABSTRACT...
Ruben A. Mesa, MD, on Myeloproliferative Neoplasms: Managing PV and ET
Ruben A. Mesa, MD, of The University of Texas Health San Antonio Cancer Center, discusses the role of JAK2 inhibitors in treating polycythemia vera and essential thrombocythemia and how to develop individualized therapy based on risk stratification.
Momelotinib vs Ruxolitinib in Janus Kinase Inhibitor–Naive Myelofibrosis
In the phase III SIMPLIFY-1 noninferiority trial reported in the Journal of Clinical Oncology, Mesa et al found that the selective Janus kinase (JAK) 1 and 2 inhibitor momelotinib was noninferior to ruxolitinib (Jakafi) in spleen response, but not symptom response, in JAK inhibitor–naive...
NCCN Panelists Relay ‘What’s Hot’ in Their Fields
AT THE NATIONAL Comprehensive Cancer Network® (NCCN®) 22nd Annual Conference, experts from several fields met with journalists to highlight “what’s hot” in their specialties. The ASCO Post captured that conversation. Myeloproliferative Neoplasms Guidelines NCCN HAS LAUNCHED new NCCN Clinical...
David H. Henry, MD, and Ruben A. Mesa, MD, on Myelofibrosis: Trial Results From a Best of ASCO Abstract
David H. Henry, MD, of Pennsylvania Oncology Hematology Associates, and Ruben A. Mesa, MD, of the Mayo Clinic Cancer Center, discuss phase III study findings on momelotinib vs ruxolitinib in JAK inhibitor–naive patients with myelofibrosis. (Abstract 7000)
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®): 2017 Guidelines
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®): 2017 Guidelines In 1996, the National Comprehensive Cancer Network® (NCCN®) published its first set of Clinical Practice Guidelines in Oncology®, covering 8 tumor types. Guidelines are now published for more than 60 tumor types and...
Ruben A. Mesa, MD, on Myeloproliferative Neoplasms and Myelofibrosis: New Treatment Guidelines 126
Ruben A. Mesa, MD, of the Mayo Clinic Cancer Center, discusses molecular abnormalities and their use in the diagnosis, risk stratification, and selection of treatment for myelofibrosis.
NCCN Issues New Clinical Practice Guidelines for Myeloproliferative Neoplasms
Myeloproliferative neoplasms are a group of blood cancers characterized by significant symptoms and a high risk of transformation into acute leukemia. These cancers—myelofibrosis, essential thrombocythemia, and polycythemia vera—affect approximately 13,000; 134,000; and 148,000 patients in the...
NCCN Publishes New Clinical Practice Guidelines for Myeloproliferative Neoplasms
Myeloproliferative neoplasms are a group of blood cancers characterized by significant symptoms and a high risk of transformation into acute leukemia. These cancers—myelofibrosis, essential thrombocythemia, and polycythemia vera—affect approximately 13,000, 134,000, and 148,000 patients ...
Ruben A. Mesa, MD, and James O. Armitage, MD, Results of the PERSIST-1 Study on Myelofibrosis
James O. Armitage, MD, of The University of Nebraska Medical Center, and Ruben A. Mesa, MD, of the Mayo Clinic, discuss pacritinib and its significant efficacy in myelofibrosis (Abstract LBA7006).
Ruben A. Mesa, MD, Summarizes Results of the PERSIST-1 Study on Myelofibrosis
Ruben A. Mesa, MD, of the Mayo Clinic, discusses pacritinib and its significant efficacy in myelofibrosis (Abstract LBA7006).
Updates on Ruxolitinib from ASCO and ASH 2012, including Long-term Survival Data
Ruxolitinib (Jakafi), a novel, oral JAK1 and JAK2 inhibitor, was approved by the FDA on November 16, 2011 for patients with intermediate- or high-risk myelofibrosis. The approval was based on its efficacy in reducing spleen size and improving disease-related burdensome symptoms. In the brief In the ...
Pacritinib for Myelofibrosis: Effective in Patients With Thrombocytopenia
An emerging JAK inhibitor, pacritinib, appears not only effective in a broad population of patients with myelofibrosis but also among a subset with very low platelet counts, investigators from the global phase III PERSIST-1 trial reported at the 2015 ASCO Annual Meeting.1 “There is a huge unmet...
ASCO 2015: JAK Inhibitor Pacritinib Proves Effective for Easing Symptoms of Myelofibrosis
Findings from the PERSIST-1 study of patients with myelofibrosis show that the JAK inhibitor pacritinib is significantly more effective than best available therapy, which includes a range of off-label treatments, for easing the symptoms of myelofibrosis. At a landmark analysis at 24 weeks of...
